Nefrología · 2018 · 12 citations · 12 references
MedicineInfectious DiseasesNephrologyHepatologyKidney TransplantationTransplant SurgeryImmunosuppression In Kidney TransplantationLiver TransplantationTransplant Infectious ComplicationsViral HepatitisHepatitis B Surface Antigen LossHepatitis B Virus PersistenceHepatitis B Virus ReactivationInfection Risk FactorsKidney Transplant CareProtective Antibody TitersSpontaneous ReactivationViral Hepatitis Reactivation
BACKGROUND: Hepatitis B virus (HBV) reactivation in kidney transplant recipients (KTR) involves important morbidity and mortality. Despite being more common in patients who are HBsAg-positive, it may occur in patients with clinically resolved infection (HBsAg-negative and anti-HBc-positive), in whom the presence of the protective anti-HB antibody is thought to decrease the risk of reactivation. Data regarding reactivation rates in this population are scarce. OBJECTIVE: To retrospectively evaluate the risk of HBV reactivation in KTR with previously resolved infection. MATERIAL AND METHODS: Retrospective cohort study including patients who underwent a kidney transplant between January 1994 and December 2014 with resolved HBV infection at the time of transplantation (anti-HBc seropositivity without detectable HBsAg, with or without anti-HB-positive antibodies and normal liver enzymes). RESULTS: Out of 966 patients, 95 patients with evidence of resolved HBV infection were analyzed, of which 86 had a titer of anti-HBs >10mIU/ml. Mean follow-up time was 93 months; 12 patients had lost anti-HBs. Two patients showed evidence of reactivation. Risk factors associated with loss of anti-HBs were elderly age (>60) and occurrence of acute graft rejection (p<0.05). CONCLUSION: The risk of HBV reactivation in KTR with previously resolved infection is not negligible at 2%. Elderly age and acute rejection were associated with loss of anti-HBs, and these patients may benefit from closer monitoring of HBV DNA levels. Routine serology and/or HBV viral load monitoring in HBsAg-negative, anti-HBc-positive patients is recommended and should be emphasized in these patients.
12
AASLD guidelines for treatment of chronic hepatitis B
Norah A. Terrault, Natalie Bzowej, Kyong‐Mi Chang et al. · Hepatology · 2015 · 2K citations
Reactivation of hepatitis B # †
Jay H. Hoofnagle · Hepatology · 2009 · 572 citations · Full text